The Polycystic Ovary Syndrome
Authors: Jennifer F. Wilson
Journal: Annals of Internal Medicine (2011)

In the Clinic1 February 2011The Polycystic Ovary SyndromeDeborah Cotton, MD, MPH, Darren Taichman, MD, Sankey Williams, MD, and Jennifer F. WilsonDeborah Cotton, MD, MPHSearch for more papers by this author, Darren Taichman, MDSearch for more papers by this author, Sankey Williams, MDSearch for more papers by this author, and Jennifer F. WilsonSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-154-3-201102010-01002 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The polycystic ovary syndrome (PCOS) is a common hormone disorder affecting women of reproductive age. Prevalence estimates vary between 5% and 15%, depending on the criteria. In recent years, recognition and understanding of the condition have improved significantly, but it is still widely underdiagnosed (1). The European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine (ESHRE/ASRM) have recommended that PCOS be diagnosed only after excluding other medical conditions that cause irregular menstrual cycles and androgen excess and only if at least 2 of the following are present: oligoovulation or anovulation, elevated levels of circulating androgens ...References1. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25:544-51. [PMID: 19910321] Google Scholar2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19-25. [PMID: 14711538] Google Scholar3. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GE (eds). Polycystic Ovary Syndrome. Current Issues in Endocrinology and Metabolism. Boston: Blackwell Scientific Publications; 1992:377. Google Scholar4. Azziz R, Carmina E, Dewailly D, et al; Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91:456-88. [PMID: 18950759] Google Scholar5. Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med. 2008;358:47-54. [PMID: 18172174] Google Scholar6. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010;95:2038-49. [PMID: 20375205] Google Scholar7. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370:685-97. [PMID: 17720020] Google Scholar8. Goodarzi MO, Quiñones MJ, Azziz R, Rotter JI, Hsueh WA, Yang H. Polycystic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance. Fertil Steril. 2005;84:766-9. [PMID: 16169421] Google Scholar9. Menke MN, Strauss JF 3rd. Genetic approaches to polycystic ovarian syndrome. Curr Opin Obstet Gynecol. 2007;19:355-9. [PMID: 17625418] Google Scholar10. Ewens KG, Stewart DR, Ankener W, et al. Family-based analysis of candidate genes for polycystic ovary syndrome. J Clin Endocrinol Metab. 2010;95:2306-15. [PMID: 20200332]. Google Scholar11. Barber TM, McCarthy MI, Wass JAH, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol. 2006;65:137-45. [PMID: 16886951] Google Scholar12. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84:165-9. [PMID: 9920077] Google Scholar13. Balen AH, Rutherford AJ. Managing anovulatory infertility and polycystic ovary syndrome. BMJ. 2007;335:663-6. [PMID: 17901517] Google Scholar14. George K, Alberti KG, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366:1059—1062 Google Scholar15. van Hooff MH, Voorhorst FJ, Kaptein MB, et al. Endocrine features of polycystic ovary syndrome in a random population sample of 14-16 year old adolescents. Hum Reprod. 1999;14:2223-9. [PMID: 10469684] Google Scholar16. Legro RS. Polycystic ovary syndrome. Phenotype to genotype. Endocrinol Metab Clin North Am. 1999;28:379-96. [PMID: 10352924] Google Scholar17. Balen AH, Conway GS, Kaltsas G, et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod. 1995;10:2107-11. [PMID: 8567849] Google Scholar18. Carmina E, Koyama T, Chang L, Stanczyk FZ, Lobo RA. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol. 1992;167:1807-12. [PMID: 1471702] Google Scholar19. Shapiro J. Clinical practice. Hair loss in women. N Engl J Med. 2007; 357: 1620-30. [PMID: 17942874] Google Scholar20. Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. Br J Obstet Gynaecol. 2006;113:1203-9. [PMID: 16753044] Google Scholar21. Alexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Obstet Gynecol. 2009;2:232-9. [PMID: 20111659] Google Scholar22. Tasali E, Van Cauter E, Ehrmann DA. Polycystic ovary syndrome and obstructive sleep apnea. Sleep Med Clin. 2008;3:37-46. [PMID: 19255602] Google Scholar23. Barnard L, Ferriday D, Guenther N, et al. Quality of life and psychological well being in polycystic ovary syndrome Hum. Reprod. 2007;22:2279-86. [PMID: 17537782] Google Scholar24. Kerchner A, Lester W, Stuart SP, Dokras A. Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study. Fertil Steril. 2009; 91 (1) :207-12. [PMID: 18249398] Google Scholar25. Franks S, White DM. Prevalence of and etiological factors in polycystic ovarian syndrome. Ann N Y Acad Sci. 1993;687:112-4. [PMID: 8323165] Google Scholar26. Balen AH, Michelmore K. What is polycystic ovary syndrome? Are national views important? Hum Reprod. 2002;17:2219-27. [PMID: 12202405] Google Scholar27. Legro R. Pregnancy considerations in women with polycystic ovary syndrome. Clin Obstet Gynecol. 2007;50:295-304. [PMID: 17304043] Google Scholar28. Robinson S, Rodin DA, Deacon A, Wheeler MJ, Clayton RN. Which hormone tests for the diagnosis of polycystic ovary syndrome? Br J Obstet Gynaecol. 1992;99:232-8. [PMID: 1296589] Google Scholar29. Koskinen P, Penttilä TA, Anttila L, Erkkola R, Irjala K. Optimal use of hormone determinations in the biochemical diagnosis of the polycystic ovary syndrome. Fertil Steril. 1996;65:517-22. [PMID: 8774279] Google Scholar30. Welt CK, Arason G, Gudmundsson JA, et al. Defining constant versus variable phenotypic features of women with polycystic ovary syndrome using different ethnic groups and populations. J Clin Endocrinol Metab. 2006;91:4361-8. [PMID: 16940441] Google Scholar31. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22:141-6. [PMID: 10333916] Google Scholar32. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16:347-63. [PMID: 20159883] Google Scholar33. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update. 2003;9:505-14. [PMID: 14714587] Google Scholar34. Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol. 2010;203:201.e1-5. [PMID: 20435290] Google Scholar35. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab. 1999;84:1470-4. [PMID: 10199797] Google Scholar36. Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab. 2000;85:2767-74. [PMID: 10946879] Google Scholar37. Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod. 2003;18:1928-32. [PMID: 12923151] Google Scholar38. Thomson RL, Buckley JD, Moran LJ, et al. The effect of weight loss on anti-Müllerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment. Hum Reprod. 2009;24:1976-81. [PMID: 19380385] Google Scholar39. Stamets K, Taylor DS, Kunselman A, Demers LM, Pelkman CL, Legro RS. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril. 2004;81:630-7. [PMID: 15037413] Google Scholar40. Azziz R. The evaluation and management of hirsutism. Obstet Gynecol. 2003;101:995-1007. [PMID: 12738163] Google Scholar41. Rittmaster RS. Antiandrogen treatment of polycystic ovary syndrome. Endocrinol Metab Clin North Am. 1999;28:409-21. [PMID: 10352926] Google Scholar42. Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:1105-20. [PMID: 18252793] Google Scholar43. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Nestler JE. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab. 2003;88:1927-32. [PMID: 12727935] Google Scholar44. Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab. 2005;90:3863-70. [PMID: 15814774] Google Scholar45. Harborne L, Fleming R, Lyall H, Norman J, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet. 2003;361:1894-901. [PMID: 12788588] Google Scholar46. Driscoll DA. Polycystic ovary syndrome in adolescence. Semin Reprod Med. 2003;21:301-7. [PMID: 14593553] Google Scholar47. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005552. [PMID: 17253562] Google Scholar48. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008;23:462-77. [PMID: 18308833] Google Scholar49. Hudecova M, Holte J, Olovsson M Sundström Poromaa I. Long-term follow-up of patients with polycystic ovary syndrome: reproductive outcome and ovarian reserve Hum Reprod. 2009;24:1176-83. [PMID: 19168874] Google Scholar50. Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356:551-66. [PMID: 17287476] Google Scholar51. Johnson NP, Stewart AW, Falkiner J, et al. PCOSMIC: a multi-centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Hum Reprod. 2010;25:1675-83. [PMID: 20435692] Google Scholar52. Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD003053. [PMID: 20091537] Google Scholar53. Bayram N, van Wely M, Kaaijk EM, Bossuyt PMM, van der Veen F. Using an electrocautery strategy or recombinant FSH to induce ovulation in polycystic ovary syndrome: a randomised controlled trial. BMJ. 2004;328:192-5. [PMID: 14739186] Google Scholar54. Farquhar C, Vandekerckhove P, Lilford R. Laparoscopic "drilling" by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev 2005;(3):CD001122. [PMID: 17636653] Google Scholar55. Stoll BA. New metabolic-endocrine risk markers in endometrial cancer. Br J Obstet Gynaecol. 1999;106:402-6. [PMID: 10430187] Google Scholar56. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223-36. [PMID: 15788499] Google Scholar57. Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update. 2001;7: 522-5. [PMID: 11727859] Google Scholar58. Boomsma CM, Fauser BC, Macklon NS. Pregnancy complications in women with polycystic ovary syndrome. Semin Reprod Med. 2008;26:72-84. [PMID: 18181085] Google Scholar59. Salley KES, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Glucose intolerance in polycystic ovary syndrome: a position statement of the Androgen Excess Society. J Clin Endocrinol Metab. 2007;92:4546-56. [PMID: 18056778] Google Scholar60. American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee. American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. Endocr Pract. 2005;11:126-34. [PMID: 15915567] Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMetabolische und reproduktionsmedizinische Aspekte des Polyzystischen Ovarsyndroms (PCOS) 1 February 2011Volume 154, Issue 3Page: ITC2-1KeywordsAndrogensInfertilityInsulin resistanceObesityOral contraceptive therapyOvariesOverweightOvulationPregnancyWeight loss ePublished: 1 February 2011 Issue Published: 1 February 2011 Copyright & PermissionsCopyright © 2011 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...